PureTech Health PLC ADR PRTCY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $15.49
- Day Range
- $15.45–15.45
- 52-Week Range
- $0.00–19.92
- Bid/Ask
- — / —
- Shares Outstanding
- 24.52M
- Market Cap
- $378.80M
- Volume/Avg
- 310 / 3,589
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 59.63
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 62
- Website
- https://www.puretechhealth.com
Valuation
|
Metric
|
PRTCY
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.98 |
Price/Sales | 59.63 |
Price/Cash Flow | — |
Price/Earnings
PRTCY
Financial Strength
|
Metric
|
PRTCY
|
|---|---|
Quick Ratio | 4.40 |
Current Ratio | 4.60 |
Interest Coverage | 0.94 |
Quick Ratio
PRTCY
Profitability
|
Metric
|
PRTCY
|
|---|---|
Return on Assets (Normalized) | −44.94% |
Return on Equity (Normalized) | −72.18% |
Return on Invested Capital (Normalized) | −57.62% |
Return on Assets
PRTCY
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|%?^!l# | LOCK|Bg%zd | $133B | |||
| Moderna Inc
MRNA
| LOCK|%s@^%^& | LOCK|v?Q | $98B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|$&FLMK# | LOCK|FcnD | $83B | |||
| argenx SE ADR
ARGX
| LOCK|M&Nb<w | LOCK|P?# | $56B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|NtF^@! | LOCK|g# | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|&&r!SQq | LOCK|?pV$p | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|v%<yprp | LOCK|kFXc# | $28B | |||
| Incyte Corp
INCY
| LOCK|RN#PXZ# | LOCK|fr | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|k&&H<Lh | LOCK|Jy^ | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|p!sfKv | LOCK|pZ | $14B |
United States